url:https://finance.yahoo.com/news/bridgebio-pharma-q3-earnings-snapshot-114506090.html
title:BridgeBio_Pharma_Q3_Earnings_Snapshot
PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $177 million in its third quarter.
The Palo Alto, California-based company said it had a loss of $1.08 per share.
The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 86 cents per share.
The rare disease drug developer posted revenue of $4.1 million in the period, also missing Street forecasts. Four analysts surveyed by Zacks expected $5.3 million.
BridgeBio Pharma shares have more than tripled since the beginning of the year. The stock has more than doubled in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BBIO at https://www.zacks.com/ap/BBIO